Selarsdi in Nepal

Selarsdi - overview

Selarsdi (seladelpar) is manufactured by CymaBay (now Gilead), verify and indicated for moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years and older, and active psoriatic arthritis in adults. It is a subcutaneous IL-12 / IL-23 p40-inhibitor biosimilar approved by the US FDA in 2024 and may be accessible to patients in Nepal through a Named Patient Program or personal-import pathway.

Access in Nepal

Nepal's DDA has a personal-use pathway; volumes are small but process exists.

How Reserve Meds coordinates access in Nepal

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Nepal-specifi